A. Elgamal

953 total citations
10 papers, 784 citations indexed

About

A. Elgamal is a scholar working on Immunology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Elgamal has authored 10 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Elgamal's work include Immunotherapy and Immune Responses (7 papers), vaccines and immunoinformatics approaches (5 papers) and Prostate Cancer Treatment and Research (3 papers). A. Elgamal is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), vaccines and immunoinformatics approaches (5 papers) and Prostate Cancer Treatment and Research (3 papers). A. Elgamal collaborates with scholars based in United States, Belgium and Egypt. A. Elgamal's co-authors include G.P. Murphy, S.J. Simmons, M.J. Troychak, Alton L. Boynton, B.A. Tjoa, M. Rogers, Gerald M. Kenny, Haakon Ragde, Michael L. Salgaller and Oliver E. Cobb and has published in prestigious journals such as The Prostate and PubMed.

In The Last Decade

A. Elgamal

10 papers receiving 744 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Elgamal United States	8	662	357	341	121	55	10	784
S.J. Simmons United States	9	717 1.1×	394 1.1×	393 1.2×	144 1.2×	66 1.2×	10	862
M. Rogers United States	9	797 1.2×	431 1.2×	416 1.2×	124 1.0×	70 1.3×	10	918
Jeff Schlom United States	3	396 0.6×	318 0.9×	180 0.5×	151 1.2×	69 1.3×	4	590
M.J. Troychak United States	10	786 1.2×	423 1.2×	439 1.3×	260 2.1×	69 1.3×	13	1.0k
Jolie Snively United States	7	630 1.0×	682 1.9×	276 0.8×	71 0.6×	49 0.9×	8	934
Elizabeth Seja United States	10	682 1.0×	770 2.2×	206 0.6×	73 0.6×	42 0.8×	12	963
Elisabeth Seja United States	7	737 1.1×	687 1.9×	193 0.6×	41 0.3×	59 1.1×	7	971
Adel L. Barsoum United States	14	448 0.7×	203 0.6×	271 0.8×	35 0.3×	25 0.5×	37	674
Sjoerd van der Burg Netherlands	9	409 0.6×	397 1.1×	123 0.4×	63 0.5×	51 0.9×	16	581
Weiqing Jing United States	15	479 0.7×	452 1.3×	225 0.7×	35 0.3×	63 1.1×	29	825

Countries citing papers authored by A. Elgamal

Since Specialization

Citations

This map shows the geographic impact of A. Elgamal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Elgamal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Elgamal more than expected).

Fields of papers citing papers by A. Elgamal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Elgamal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Elgamal. The network helps show where A. Elgamal may publish in the future.

Co-authorship network of co-authors of A. Elgamal

This figure shows the co-authorship network connecting the top 25 collaborators of A. Elgamal. A scholar is included among the top collaborators of A. Elgamal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Elgamal. A. Elgamal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Elgamal, A. & Gihan Hosny. (2009). Assessment of lung cancer risk due to exposure to radon from coastal sediments.. PubMed. 14(6). 1257–69. 8 indexed citations

2.

Murphy, G.P., et al.. (2000). Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint� scintiscans. The Prostate. 42(2). 145–149. 22 indexed citations

3.

Simmons, S.J., B.A. Tjoa, M. Rogers, et al.. (1999). GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. The Prostate. 39(4). 291–297. 59 indexed citations

4.

Tjoa, B.A., S.J. Simmons, A. Elgamal, et al.. (1999). Follow-up evaluation of a phase II prostate cancer vaccine trial. The Prostate. 40(2). 125–129. 121 indexed citations

5.

Murphy, G.P., B.A. Tjoa, S.J. Simmons, et al.. (1999). Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. The Prostate. 38(1). 73–78. 197 indexed citations

6.

Murphy, G.P., B.A. Tjoa, S.J. Simmons, et al.. (1999). Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. The Prostate. 39(1). 54–59. 153 indexed citations

7.

Tjoa, B.A., S.J. Simmons, A. Elgamal, et al.. (1999). Follow‐up evaluation of a phase II prostate cancer vaccine trial. The Prostate. 40(2). 125–129. 9 indexed citations

8.

Murphy, G.P., B.A. Tjoa, S.J. Simmons, et al.. (1999). Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. The Prostate. 39(1). 54–59. 7 indexed citations

9.

Tjoa, B.A., S.J. Simmons, Victoria Bowes, et al.. (1998). Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. The Prostate. 36(1). 39–44. 207 indexed citations

10.

Ridder, Dirk De, A. Elgamal, Patrick Werbrouck, et al.. (1994). [Hormone therapy before radical prostatectomy. Effects on surgical method and resection margins. Belgian Uro-Oncological Study Group (B.U.O.S.)].. PubMed. 62(1). 61–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact